Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma

Research output: Contribution to journalArticlepeer-review


Immune checkpoint inhibitors such as anti-CTLA-4 and anti-PD-1/PD-L1 monoclonal antibodies have dramatically changed the paradigm of cancer therapy over the past few years. The use of these agents is associated with a unique pattern of autoimmune-like/inflammatory side effects termed immune-related adverse events (irAEs), that may cause collateral damage to normal tissues. Although severe irAEs remain rare, they can become life-threatening if not anticipated and managed appropriately. Improving our knowledge of the mechanisms underlying the development of these toxicities is crucial to optimize clinical efficacy and safety of these new immunotherapeutics. Herein we describe for the first time the pathological features of a severe liver-injury associated with the administration of the anti-PD-1 agent nivolumab in a patient with glioblastoma.

Original languageEnglish
Pages (from-to)1363-1369
Number of pages7
Issue number12
Publication statusPublished - Dec 1 2016


  • anti-PD-1/L-1 agents
  • hepatitis
  • immune-related adverse events

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology


Dive into the research topics of 'Pathological characterization of nivolumab-related liver injury in a patient with glioblastoma'. Together they form a unique fingerprint.

Cite this